Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective

Blagden SP. et al, (2022), British journal of cancer

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.

Jones R. et al, (2022), Clin cancer res

First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.

Davis EJ. et al, (2022), J immunother cancer, 10

Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.

Clamp AR. et al, (2022), Lancet oncol

PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials

Nicum S. and Blagden SP., (2022), Clinical cancer research

Inhibiting the Priming for Cancer in Li-Fraumeni Syndrome.

Pantziarka P. and Blagden S., (2022), Cancers (basel), 14

Targeting MAPK in recurrent, low-grade serous ovarian cancer.

Blagden SP., (2022), Lancet (london, england), 399, 499 - 501

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer

Kazmi F. et al, (2021), Cochrane database of systematic reviews, 2021

The novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial.

Schwenzer H. et al, (2021), Clin cancer res

Include forthcoming?